

\* ----- ILTE STUDY NEWSLETTER – September 2008 -----\*

Dear ILTE investigators,

as decided by the ILTE Steering Committee in June, an abstract (IMATINIB LONG TERM EFFECTS (ILTE) STUDY: AN INTERNATIONAL STUDY TO EVALUATE LONG-TERM EFFECTS IN CML PATIENTS) was submitted to ASH.

Because of space reasons, only the centers that enrolled >35 patients could be included as formal coauthors, although everybody will be acknowledged in the presentation, and everybody (with at least 10 eligible patients) will coauthor the publication.

I attach here the abstract submitted to ASH; you must treat it as confidential until the ASH meeting.

Should you want to present the ILTE preliminary results to a regional meeting, let me know so we can arrange a suitable author list based on a rotation basis.

Similarly, I am looking at submitting ILTE abstracts at ASCO and EHA; let me know if you plan to attend one of these two meetings, especially ASCO.

With best regards,

Carlo Gambacorti MD  
ILTE Chairman